ReShape Lifesciences Inc. Common Stock
RSLS
RSLS was delisted on the 28th of December, 2018.
11 hedge funds and large institutions have $5.88M invested in ReShape Lifesciences Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
+$4.1M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$1.24M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$437K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$344K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$43K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NLVP
1
New Leaf Venture Partners
New York
| $3.85M | +$4.1M | +1,239 | New |
|
|
IBT
2
International Biotechnology Trust
London,
United Kingdom
| $1.15M | +$1.24M | +375 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $410K | +$437K | +132 | New |
|
|
AFM
4
Anson Funds Management
Dallas,
Texas
| $324K | +$344K | +104 | New |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $39K | +$43K | +13 | New |
|
6
US Bancorp
Minneapolis,
Minnesota
| $37K | +$39.7K | +12 | New |
|
7
Goldman Sachs
New York
| $33K | +$36.4K | +11 | New |
|
8
BlackRock
New York
| $27K | +$29.8K | +9 | New |
|
9
Morgan Stanley
New York
| $5K | +$6.62K | +2 | New |
|
10
Parallax Volatility Advisers
San Francisco,
California
| $2K | +$3.31K | +1 | New |
|
11
UBS Group
Zurich,
Switzerland
| $2K | +$3.31K | +1 | New |
|
12
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
FANJ
13
Financial Architects (New Jersey)
Marlton,
New Jersey
| $1K | – | – | – |
|
|
SWM
14
SeaCrest Wealth Management
Purchase,
New York
| $1K | – | – | – |
|
RSLS Hedge Fund Activity: Q4 2017 in Review
11 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in ReShape Lifesciences Inc. Common Stock (RSLS) for Q4 2017, worth a combined $5.88M.
Buyers outnumbered sellers: 11 funds opened new RSLS positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $4.1M.
- 11 institutional investors held ReShape Lifesciences Inc. Common Stock (RSLS) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $5.88M of ReShape Lifesciences Inc. Common Stock stock for Q4 2017.
- 11 funds opened new ReShape Lifesciences Inc. Common Stock positions in Q4 2017 and 0 closed out, a net change of +11 holders.
- The largest ReShape Lifesciences Inc. Common Stock buyer in Q4 2017 was New Leaf Venture Partners, an estimated $4.1M added.
Based on aggregated 13F filings for Q4 2017.